89bio, Inc.

NasdaqGM:ETNB Voorraadrapport

Marktkapitalisatie: US$968.0m

89bio Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

89bio has a total shareholder equity of $514.9M and total debt of $25.1M, which brings its debt-to-equity ratio to 4.9%. Its total assets and total liabilities are $582.1M and $67.2M respectively.

Belangrijke informatie

4.9%

Verhouding schuld/eigen vermogen

US$25.13m

Schuld

Rente dekkingsration/a
ContantUS$531.38m
AandelenUS$514.92m
Totaal verplichtingenUS$67.22m
Totaal activaUS$582.14m

Recente financiële gezondheidsupdates

Recent updates

89bio: Surviving A Competitive Space - For Now

Oct 29

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

Sep 26
Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

89bio Still Has A Chance As NASH Race Heats Up

Oct 06

89bio completes enrollment in phase 2 trial for NASH treatment

Aug 18

89Bio rallies on Deep Track Capital disclosing 10% stake

Jul 07

89bio: Undervalued Contender In Race For First NASH Drug Approval

Jul 20

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

May 07
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio: NASH Drug Developer With Differentiated Profile

Jan 29

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

Jan 22
We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

89bio expects to initiate Phase 2b NASH trial in 1H21

Jan 05

Analyse van de financiële positie

Kortlopende schulden: ETNB's short term assets ($579.9M) exceed its short term liabilities ($41.7M).

Langlopende schulden: ETNB's short term assets ($579.9M) exceed its long term liabilities ($25.6M).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ETNB has more cash than its total debt.

Schuld verminderen: ETNB's debt to equity ratio has increased from 0% to 4.9% over the past 5 years.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ETNB has sufficient cash runway for more than 3 years based on its current free cash flow.

Voorspelling contante baan: ETNB has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 35.2% each year.


Ontdek gezonde bedrijven